Short-Term Combined Treatment With Tirzepatide and Metformin for Overweight/Obese Chinese Women With Polycystic Ovary Syndrome: A Prospective, Open-Label, Randomised Controlled Trial
Adding a newer diabetes drug to metformin nearly triples weight loss and restores menstrual cycles in women with polycystic ovary syndrome, improving fertility prospects.
This small RCT (n=60) in obese PCOS women shows tirzepatide + metformin achieves 10.4 kg weight loss vs 1.7 kg with metformin alone at 16 weeks, with significant improvements in reproductive endocrine outcomes, menstrual regularity, and pregnancy rates. Despite small size, the RCT design and multi-endpoint reproductive benefits make this clinically relevant for this underserved population.
What the study was
- Study design
- Prospective open-label RCT, 16-week treatment + follow-up
- Population
- Overweight/obese Chinese women with PCOS
- Sample size
- 60
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Diabetes Obes Metab
Why it surfaced
RCT in PCOS — a condition with limited targeted therapy options. Tirzepatide's metabolic-reproductive dual benefits here are novel. n=60 limits power but RCT design is appropriate.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.